Cancers 2010, 2(2), 955-969; doi:10.3390/cancers2020955
Review

Systemic Therapy of Non-Resectable Metastatic Melanoma

Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany
* Author to whom correspondence should be addressed.
Received: 8 March 2010; in revised form: 11 May 2010 / Accepted: 12 May 2010 / Published: 26 May 2010
PDF Full-text Download PDF Full-Text [123 KB, uploaded 26 May 2010 10:03 CEST]
Abstract: In advanced metastatic melanoma (non-resectable stage III/IV), the prognosis still remains poor, with median survival times between six and twelve months. Systemic therapeutic approaches for metastatic melanoma include chemotherapy, immunotherapy, immunochemotherapy, small molecules and targeted therapy. In this review, we will focus on the various treatment modalities as well as new agents used for targeted therapy.
Keywords: melanoma; metastatic; chemotherapy; targeted therapy; small molecules

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Orouji, A.; Goerdt, S.; Utikal, J. Systemic Therapy of Non-Resectable Metastatic Melanoma. Cancers 2010, 2, 955-969.

AMA Style

Orouji A, Goerdt S, Utikal J. Systemic Therapy of Non-Resectable Metastatic Melanoma. Cancers. 2010; 2(2):955-969.

Chicago/Turabian Style

Orouji, Azadeh; Goerdt, Sergij; Utikal, Jochen. 2010. "Systemic Therapy of Non-Resectable Metastatic Melanoma." Cancers 2, no. 2: 955-969.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert